Europe Active Pharmaceutical Ingredient Cdmo Market Size & Outlook

The active pharmaceutical ingredient cdmo market in Europe is expected to reach a projected revenue of US$ 43,875.7 million by 2030. A compound annual growth rate of 7.2% is expected of Europe active pharmaceutical ingredient cdmo market from 2024 to 2030.
Revenue, 2023 (US$M)
$26,900.0
Forecast, 2030 (US$M)
$43,875.7
CAGR, 2024 - 2030
7.2%
Report Coverage
Europe

Europe active pharmaceutical ingredient cdmo market, 2018-2030 (US$M)

Europe

Related Markets

Europe active pharmaceutical ingredient cdmo market highlights

  • The Europe active pharmaceutical ingredient cdmo market generated a revenue of USD 26,900.0 million in 2023.
  • The market is expected to grow at a CAGR of 7.2% from 2024 to 2030.
  • In terms of segment, traditional active pharmaceutical ingredient (traditional api) was the largest revenue generating product in 2023.
  • Antibody Drug Conjugate (ADC is the most lucrative product segment registering the fastest growth during the forecast period.
  • Country-wise, Germany is expected to register the highest CAGR from 2024 to 2030.


Europe data book summary

Market revenue in 2023USD 26,900.0 million
Market revenue in 2030USD 43,875.7 million
Growth rate7.2% (CAGR from 2023 to 2030)
Largest segmentTraditional active pharmaceutical ingredient (traditional api)
Fastest growing segmentAntibody Drug Conjugate (ADC
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationTraditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC
Key market players worldwideRecipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma


Other key industry trends

  • In terms of revenue, Europe region accounted for 22.7% of the global active pharmaceutical ingredient cdmo market in 2023.
  • Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 76,520.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Active Pharmaceutical Ingredient CDMO Market Scope

Active pharmaceutical ingredient cdmo market segmentation & scope
Traditional Active Pharmaceutical Ingredient (Traditional API)
Highly Potent Active Pharmaceutical Ingredient (HP-API)
Antibody Drug Conjugate (ADC
Others
Synthetic
Biotech
Innovative
Generics
Clinical
Commercial
Oncology
Hormonal
Glaucoma
Cardiovascular disease
Diabetes
Others

Active Pharmaceutical Ingredient CDMO Market Companies

Name Profile # Employees HQ Website

Europe active pharmaceutical ingredient cdmo market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.


Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 39.79% in 2023. Horizon Databook has segmented the Europe active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.


Europe’s market held the third-largest share of 16.1% in 2020. It is one of the leading regions with advanced technologies and well-established infrastructure, resulting in improved healthcare facilities & patient care. Regulatory framework in the EU is expected to be subjected to major changes, which may affect market access or entry.

The market is expected to grow lucratively in this region due to stringent regulatory policies. To import active substances in Europe, the APIs should be manufactured in compliance with Good Manufacturing Practices (GMP), at least equivalent to the EU GMPs.

Presence of established market players, coupled with superior manufacturing capabilities, is anticipated to drive the market over the forecast period. Furthermore, increasing investments by multinational companies is anticipated to boost the market.

Reasons to subscribe to Europe active pharmaceutical ingredient cdmo market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe active pharmaceutical ingredient cdmo market databook

  • Our clientele includes a mix of active pharmaceutical ingredient cdmo market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Europe active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Europe active pharmaceutical ingredient cdmo market size, by country, 2018-2030 (US$M)

Europe Active Pharmaceutical Ingredient CDMO Market Outlook Share, 2023 & 2030 (US$M)

Europe active pharmaceutical ingredient cdmo market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more